DTIL – Precision BioSciences, Inc.

Float Short %

3.29

Margin Of Safety %

Put/Call OI Ratio

0.37

EPS Next Q Diff

1.02

EPS Last/This Y

-7.21

EPS This/Next Y

3.05

Price

5.01

Target Price

32.5

Analyst Recom

Performance Q

10.89

Relative Volume

0.74

Beta

1.19

Ticker: DTIL

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-17	DTIL	5.12	0.00	999.99	365
2025-11-18	DTIL	5.2	N/A	N/A	0
2025-11-19	DTIL	4.83	0.00	0.00	366
2025-11-20	DTIL	4.97	0.00	0.00	372
2025-11-21	DTIL	4.99	0.00	0.00	372
2025-11-24	DTIL	5.09	0.00	0.00	372
2025-11-25	DTIL	4.88	0.00	0.00	372
2025-11-26	DTIL	5.09	0.00	0.00	372
2025-12-01	DTIL	4.95	0.00	999.99	32
2025-12-02	DTIL	4.8	0.06	0.00	34
2025-12-03	DTIL	5.06	0.06	0.00	34
2025-12-04	DTIL	5.02	0.04	0.00	55
2025-12-05	DTIL	5	0.19	4.31	75
2025-12-08	DTIL	4.75	0.84	999.99	140
2025-12-09	DTIL	4.85	0.97	999.99	150
2025-12-10	DTIL	5	1.04	0.00	165
2025-12-11	DTIL	4.92	0.76	0.07	195
2025-12-12	DTIL	5.01	0.37	2.94	346
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-17	DTIL	5.14	59.3	-	-6.57
2025-11-18	DTIL	5.20	59.3	-	-6.57
2025-11-19	DTIL	4.82	59.3	-	-6.57
2025-11-20	DTIL	4.97	59.3	-	-6.57
2025-11-21	DTIL	4.99	66.1	-	-6.41
2025-11-24	DTIL	5.10	66.1	-	-6.41
2025-11-25	DTIL	4.88	66.1	-	-6.41
2025-11-26	DTIL	5.09	66.1	-	-6.41
2025-12-01	DTIL	4.96	66.1	-	-6.41
2025-12-02	DTIL	4.79	66.1	-	-6.41
2025-12-03	DTIL	5.06	66.1	-	-6.41
2025-12-04	DTIL	5.02	66.1	-	-6.41
2025-12-05	DTIL	5.02	66.1	-	-6.41
2025-12-08	DTIL	4.76	66.1	-	-6.41
2025-12-09	DTIL	4.86	66.1	-	-6.41
2025-12-10	DTIL	5.01	66.1	-	-6.41
2025-12-11	DTIL	4.90	66.1	-	-6.41
2025-12-12	DTIL	5.01	69.9	-	-6.16
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-17	DTIL	-0.36	9.05	4.57
2025-11-18	DTIL	-0.36	9.05	4.57
2025-11-19	DTIL	-0.36	9.05	4.57
2025-11-20	DTIL	-0.36	9.05	4.57
2025-11-21	DTIL	-0.36	9.05	4.57
2025-11-24	DTIL	-0.36	1.04	4.57
2025-11-25	DTIL	-0.36	1.04	4.57
2025-11-26	DTIL	-0.36	1.04	5.01
2025-12-01	DTIL	-0.36	1.04	5.01
2025-12-02	DTIL	-0.36	1.04	5.01
2025-12-03	DTIL	-0.36	1.04	5.00
2025-12-04	DTIL	-0.20	1.04	0
2025-12-05	DTIL	-0.20	1.04	2.76
2025-12-08	DTIL	-0.20	1.04	2.76
2025-12-09	DTIL	-0.20	1.04	2.76
2025-12-10	DTIL	-0.20	1.04	3.29
2025-12-11	DTIL	-0.20	1.04	3.29
2025-12-12	DTIL	-0.20	1.04	3.29
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="DTIL" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-1.84

Avg. EPS Est. Current Quarter

-0.64

Avg. EPS Est. Next Quarter

-0.82

Insider Transactions

-0.2

Institutional Transactions

1.04

Beta

1.19

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-99.2

Target Price

32.5

P/E

Forward P/E

PEG

P/S

171.59

P/B

3.62

P/Free Cash Flow

EPS

-8.4

Average EPS Est. Cur. Y

-6.16

EPS Next Y. (Est.)

-3.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-11977.36

Relative Volume

0.74

Return on Equity vs Sector %

-529.5

Return on Equity vs Industry %

-514.5

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.25

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”DTIL” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”DTIL” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”DTIL” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”DTIL” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”DTIL” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”DTIL” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”DTIL” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

Precision BioSciences, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 67

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

stock quote shares DTIL – Precision BioSciences, Inc. Stock Price stock today

news today DTIL – Precision BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch DTIL – Precision BioSciences, Inc. yahoo finance google finance

stock history DTIL – Precision BioSciences, Inc. invest stock market

stock prices DTIL premarket after hours

ticker DTIL fair value insiders trading

DTIL – Precision BioSciences, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: DTIL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y